Live federal data · NADAC weekly · Part D CY24

Secukinumab Ixekizumab

Secukinumab vs Ixekizumab — $3.63B of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Interleukin-17A Antagonist
Secukinumab
Brand: COSENTYX
First FDA approval:
Interleukin-17A Antagonist
Ixekizumab
Brand: TALTZ
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$3961.25Per unit
$7369.27Per unit
Average NADACAcross all dosage forms and strengths
$5561.15Up to $7923.31
$7402.57Up to $7435.87
Generic manufacturersActive ANDA holders — FDA Orange Book
00 total ANDAs filed
00 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$2.59BFull year
$1.04BFull year
Part D claims (CY24)Total fills, all strengths
290K55K beneficiaries
125K25K beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$8,926Per claim, all NDCs
$8,363Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
1032Substantial friction
88Minimal friction
Step therapy appliedPlan-NDC pairs requiring step therapy
0None
0None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
NoneClear
Generic availableFDA Orange Book
NoBrand-only
NoBrand-only